← All trials
NCT06820268
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 14, 2025
- Primary completion
- Nov 1, 2027
- Completion date
- Mar 15, 2028
- First posted
- Feb 11, 2025
- Last posted
- Mar 4, 2025
- Enrollment
- 168
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NovaOnco Therapeutics Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.